Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review

  • Hai Quang Pham (Department of Health Economics, School of Preventive Medicine and Public Health, Hanoi Medical University) ;
  • Kiet Huy Tuan Pham (Department of Health Economics, School of Preventive Medicine and Public Health, Hanoi Medical University) ;
  • Giang Hai Ha (Institute of Theoretical and Applied Research, Duy Tan University) ;
  • Tin Trung Pham (Can Tho University of Medicine and Pharmacy, Faculty of Public Health) ;
  • Hien Thi Nguyen (Can Tho University of Medicine and Pharmacy, Faculty of Public Health) ;
  • Trang Huyen Thi Nguyen (Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center) ;
  • Jin-Kyoung Oh (Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center)
  • Received : 2023.07.17
  • Accepted : 2024.02.05
  • Published : 2024.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Globally, providing evidence on the economic burden of chronic obstructive pulmonary disease (COPD) is becoming essential as it assists the health authorities to efficiently allocate resources. This study aimed to summarize the literature on economic burden evidence for COPD from 1990 to 2019. This study examined the economic burden of COPD through a systematic review of studies from 1990 to 2019. A search was done in online databases, including Web of Science, PubMed/Medline, Scopus, and the Cochrane Library. After screening 12,734 studies, 43 articles that met the inclusion criteria were identified. General study information and data on direct, indirect, and intangible costs were extracted and converted to 2018 international dollars (Int$). Findings revealed that the total direct costs ranged from Int$ 52.08 (India) to Int$ 13,776.33 (Canada) across 16 studies, with drug costs rannging from Int$ 70.07 (Vietnam) to Int$ 8,706.9 (China) in 11 studies. Eight studies explored indirect costs, while one highlighted caregivers' direct costs at approximately Int$ 1,207.8 (Greece). This study underscores the limited research on COPD caregivers' economic burdens, particularly in developing countries, emphasizing the importance of increased research support, particularly in high-resource settings. This study provides information about the demographics and economic burden of COPD from 1990 to 2019. More strategies to reduce the frequency of hospital admissions and acute care services should be implemented to improve the quality of COPD patients' lives and reduce the disease's rising economic burden.

Keywords

Acknowledgement

This work was supported by the Domestic Master/PhD Scholarship Program of Vingroup Innovation Foundation. One of the authors, Trang Huyen Thi Nguyen, received funding from the International Cooperation and Education Program (NCCRI·NCCI 52210-52211, 2023) of the National Cancer Center, Korea.

References

  1. World Health Organization. Chronic obstructive pulmonary disease (COPD) [Internet]. Geneva: WHO; 2023 [cited 2024 Mar 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
  2. Xie M, Liu X, Cao X, Guo M, Li X. Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. Respir Res 2020;21:49.
  3. Alemie GA. Exploration of healthcare workers' perceptions on occupational risk of HIV transmission at the University of Gondar Hospital, Northwest Ethiopia. BMC Res Notes 2012;5:704.
  4. Bloom DE, Cafiero ET, Jane-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al. The global economic burden of noncommunicable diseases. Geneva: World Economic Forum; 2011.
  5. Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis 2018;13:2301-11. https://doi.org/10.2147/COPD.S163795
  6. Uddin MJ, Alam N, Koehlmoos TP, Sarma H, Chowdhury MA, Alam DS, et al. Consequences of hypertension and chronic obstructive pulmonary disease, healthcare-seeking behaviors of patients, and responses of the health system: a population-based cross-sectional study in Bangladesh. BMC Public Health 2014;14:547.
  7. Menzin J, Boulanger L, Marton J, Guadagno L, Dastani H, Dirani R, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008;102:1248-56. https://doi.org/10.1016/j.rmed.2008.04.009
  8. Essue B, Kelly P, Roberts M, Leeder S, Jan S. We can't afford my chronic illness!: the out-of-pocket burden associated with managing chronic obstructive pulmonary disease in western Sydney, Australia. J Health Serv Res Policy 2011;16:226-31. https://doi.org/10.1258/jhsrp.2011.010159
  9. Kang HA, Barner JC. The relationship between out-of-pocket healthcare expenditures and insurance status among individuals with chronic obstructive pulmonary disease. J Pharm Health Serv Res 2017;8:107-13. https://doi.org/10.1111/jphs.12170
  10. Harman JS, Kelleher KJ, Reynolds CF, Pincus HA. Out-of-pocket healthcare expenditures of older Americans with depression. J Am Geriatr Soc 2004;52:809-13. https://doi.org/10.1111/j.1532-5415.2004.52224.x
  11. Patricoski CT, Steiner G. Cost of medications for patients with ischemic heart disease in a rural family practice center. J Am Board Fam Pract 1999;12:200-5. https://doi.org/10.3122/jabfm.12.3.200
  12. Souliotis K, Kousoulakou H, Hillas G, Tzanakis N, Toumbis M, Vassilakopoulos T. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis 2017;12:1395-400. https://doi.org/10.2147/COPD.S132825
  13. Ahn E, Kang H. Introduction to systematic review and meta-analysis. Korean J Anesthesiol 2018;71:103-12. https://doi.org/10.4097/kjae.2018.71.2.103
  14. Gregersen TL, Green A, Frausing E, Ringbaek T, Brondum E, Suppli Ulrik C. Do telemedical interventions improve quality of life in patients with COPD?: a systematic review. Int J Chron Obstruct Pulmon Dis 2016;11:809-22.
  15. Lenferink A, Brusse-Keizer M, van der Valk PD, Frith PA, Zwerink M, Monninkhof EM, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017;8:CD011682.
  16. Ambrosino N, Bertella E. Lifestyle interventions in prevention and comprehensive management of COPD. Breathe (Sheff) 2018;14:186-94. https://doi.org/10.1183/20734735.018618
  17. Lokke A, Lange P, Lykkegaard J, Ibsen R, Andersson M, de Fine Licht S, et al. Economic burden of COPD by disease severity: a nationwide cohort study in Denmark. Int J Chron Obstruct Pulmon Dis 2021;16:603-13. https://doi.org/10.2147/COPD.S295388
  18. Larsen DL, Gandhi H, Pollack M, Feigler N, Patel S, Wise RA. The quality of care and economic burden of COPD in the United States: considerations for managing patients and improving outcomes. Am Health Drug Benefits 2022;15:57-64.
  19. Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis 2020;15:439-60. https://doi.org/10.2147/COPD.S234942
  20. Gordon SB, Bruce NG, Grigg J, Hibberd PL, Kurmi OP, Lam KB, et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med 2014;2:823-60. https://doi.org/10.1016/S2213-2600(14)70168-7
  21. Organisation for Economic Co-operation and Development. Conversion rates: purchasing power parities (PPP) (indicator) [Internet]. Paris: OECD; 2023 [cited 2024 Mar 4]. Available from: https://doi.org/10.1787/067eb6ec-en.
  22. Jones P, Harding G, Wiklund I, Berry P, Leidy N. Improving the process and outcome of care in COPD: development of a standardised assessment tool. Prim Care Respir J 2009;18:208-15. https://doi.org/10.4104/pcrj.2009.00053
  23. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85 Suppl B:25-31. https://doi.org/10.1016/S0954-6111(06)80166-6
  24. Elmstahl S, Malmberg B, Annerstedt L. Caregiver's burden of patients 3 years after stroke assessed by a novel caregiver burden scale. Arch Phys Med Rehabil 1996;77:177-82. https://doi.org/10.1016/S0003-9993(96)90164-1
  25. Bourbeau J, Granados D, Roze S, Durand-Zaleski I, Casan P, Kohler D, et al. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program. Int J Chron Obstruct Pulmon Dis 2019;14:645-57. https://doi.org/10.2147/COPD.S173057
  26. Zhang J, Yao W, You X, Liu T, Liu Y. Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China. Int J Chron Obstruct Pulmon Dis 2019;14:1195-207. https://doi.org/10.2147/COPD.S182015
  27. Bhadhuri A, Al-Janabi H, Jowett S, Jolly K. Incorporating household spillovers in cost utility analysis: a case study using behavior change in COPD. Int J Technol Assess Health Care 2019;35:212-20. https://doi.org/10.1017/S026646231900028X
  28. Dal Negro RW. COPD: the annual cost-of-illness during the last two decades in Italy, and its mortality predictivity power. Healthcare (Basel) 2019;7:35.
  29. Fu PK, Yang MC, Wang CY, Lin SP, Kuo CT, Hsu CY, et al. Early do-not- resuscitate directives decrease invasive procedures and health care expenses during the final hospitalization of life of COPD patients. J Pain Symptom Manage 2019;58:968-76.
  30. Koul PA, Nowshehr AA, Khan UH, Jan RA, Shah SU. Cost of severe chronic obstructive pulmonary disease exacerbations in a high burden region in North India. Ann Glob Health 2019;85:13.
  31. Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N. The economic burden of chronic obstructive pulmonary disease in Greece. Appl Health Econ Health Policy 2019;17:111-21. https://doi.org/10.1007/s40258-018-0431-5
  32. Lambe T, Adab P, Jordan RE, Sitch A, Enocson A, Jolly K, et al. Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care. Thorax 2019;74:730-9. https://doi.org/10.1136/thoraxjnl-2018-212148
  33. Paly VF, Naya I, Gunsoy NB, Driessen MT, Risebrough N, Briggs A, et al. Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. Int J Chron Obstruct Pulmon Dis 2019;14:939-51. https://doi.org/10.2147/COPD.S188898
  34. Sichali JM, Khan JA, Gama EM, Banda HT, Namakhoma I, Bongololo G, et al. Direct costs of illness of patients with chronic cough in rural Malawi-experiences from Dowa and Ntchisi districts. PLoS One 2019;14:e0225712.
  35. Trudo F, Kallenbach L, Vasey J, Chung Y, Wilk A, Slipski L, et al. Clinical and economic burden of eosinophilic COPD in a large retrospective US cohort. Int J Chron Obstruct Pulmon Dis 2019;14:2625-37. https://doi.org/10.2147/COPD.S220009
  36. Viinanen A, Lassenius MI, Toppila I, Karlsson A, Veijalainen L, Idanpaan-Heikkila JJ, et al. The burden of chronic obstructive pulmonary disease (COPD) in Finland: impact of disease severity and eosinophil count on healthcare resource utilization. Int J Chron Obstruct Pulmon Dis 2019;14:2409-21. https://doi.org/10.2147/COPD.S222581
  37. Vo TQ, Phung TC, Vu TQ, Tran TN, Vo T, Phan VH, et al. Cost trend analysis of chronic obstructive pulmonary disease among Vietnamese patients: findings from two provincial facilities 2015-2017. J Clin Diagn Res 2018;12:LC92-8. https://doi.org/10.7860/JCDR/2018/36668.11715
  38. Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J. What is the impact of GOLD 2017 recommendations in primary care?: a descriptive study of patient classifications, treatment burden and costs. Int J Chron Obstruct Pulmon Dis 2018;13:3485-92. https://doi.org/10.2147/COPD.S173664
  39. Lakiang T, Nair NS, Ramaswamy A, Singhal U. Economic impact of chronic obstructive pulmonary disease: a cross-sectional study at teaching hospital in South India. J Family Med Prim Care 2018;7:1002-6. https://doi.org/10.4103/jfmpc.jfmpc_75_16
  40. Lisspers K, Larsson K, Johansson G, Janson C, Costa-Scharplatz M, Gruenberger JB, et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. Int J Chron Obstruct Pulmon Dis 2018;13:275-85. https://doi.org/10.2147/COPD.S149633
  41. Merino M, Villoro R, Hidalgo-Vega A, Carmona C. Social economic costs of COPD in Extremadura (Spain): an observational study. Int J Chron Obstruct Pulmon Dis 2018;13:2501-14. https://doi.org/10.2147/COPD.S167357
  42. Poder TG, Kouakou CR, Bouchard PA, Tremblay V, Blais S, Maltais F, et al. Cost-effectiveness of FreeO2 in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec. BMJ Open 2018;8:e018835.
  43. Stafyla E, Geitona M, Kerenidi T, Economou A, Daniil Z, Gourgoulianis KI. The annual direct costs of stable COPD in Greece. Int J Chron Obstruct Pulmon Dis 2018;13:309-15. https://doi.org/10.2147/COPD.S148051
  44. Verma AA, Guo Y, Kwan JL, Lapointe-Shaw L, Rawal S, Tang T, et al. Prevalence and costs of discharge diagnoses in inpatient general internal medicine: a multi-center cross-sectional study. J Gen Intern Med 2018;33:1899-904. https://doi.org/10.1007/s11606-018-4591-7
  45. Dal Negro RW, Celli BR. Patient related outcomes-BODE (PRO-BODE): a composite index incorporating health utilization resources predicts mortality and economic cost of COPD in real life. Respir Med 2017;131:175-8. https://doi.org/10.1016/j.rmed.2017.08.019
  46. Kamusheva M, Dimitrova M, van Boven JF, Postma MJ, van der Molen T, Kocks JW, et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. J Med Econ 2017;20:503-9. https://doi.org/10.1080/13696998.2017.1279620
  47. Ronaldson SJ, Raghunath A, Torgerson DJ, Van Staa T. Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data. ERJ Open Res 2017;3:00085-2016. https://doi.org/10.1183/23120541.00085-2016
  48. Stafyla E, Kerenidi T, Gerogianni I, Geitona M, Daniil Z, Gourgoulianis KI. The pharmacological cost of COPD during Greek economic crisis. Int J Chron Obstruct Pulmon Dis 2017;12:461-6. https://doi.org/10.2147/COPD.S123095
  49. Wacker ME, Kitzing K, Jorres RA, Leidl R, Schulz H, Karrasch S, et al. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. https://doi.org/10.2147/COPD.S141852
  50. Yoo KH, Ahn HR, Park JK, Kim JW, Nam GH, Hong SK, et al. Burden of respiratory disease in Korea: an observational study on allergic rhinitis, asthma, COPD, and rhinosinusitis. Allergy Asthma Immunol Res 2016;8:527-34. https://doi.org/10.4168/aair.2016.8.6.527
  51. Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis 2016;11:2625-32. https://doi.org/10.2147/COPD.S118523
  52. de la Rosa D, Martinez-Garcia MA, Olveira C, Giron R, Maiz L, Prados C. Annual direct medical costs of bronchiectasis treatment: impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chron Respir Dis 2016;13:361-71. https://doi.org/10.1177/1479972316643698
  53. Eklund O, Afzal F, Borgstrom F, Flavin J, Ternouth A, Ojanguren ME, et al. Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK. Clinicoecon Outcomes Res 2016;8:243-52. https://doi.org/10.2147/CEOR.S105579
  54. Thanaviratananich S, Cho SH, Ghoshal AG, Muttalif AR, Lin HC, Pothirat C, et al. Burden of respiratory disease in Thailand: results from the APBORD observational study. Medicine (Baltimore) 2016;95:e4090.
  55. Dal Negro RW, Bonadiman L, Turco P, Tognella S, Iannazzo S. Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update. Clinicoecon Outcomes Res 2015;7:153-9. https://doi.org/10.2147/CEOR.S77504
  56. Lokke A, Hilberg O, Tonnesen P, Ibsen R, Kjellberg J, Jennum P. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. BMJ Open 2014;4:e004069.
  57. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013 Jun 17;5:235-45. https://doi.org/10.2147/CEOR.S34321
  58. Maleki-Yazdi MR, Kelly SM, Lam SY, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J 2012;19:319-24. https://doi.org/10.1155/2012/328460
  59. Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD 2011;8:293-9. https://doi.org/10.3109/15412555.2011.586659
  60. Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010;5:341-9. https://doi.org/10.2147/COPD.S13771
  61. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007;61:1112-20. https://doi.org/10.1111/j.1742-1241.2007.01424.x
  62. Miller JD, Foster T, Boulanger L, Chace M, Russell MW, Marton JP, et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2005;2:311-8. https://doi.org/10.1080/15412550500218221
  63. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003;97 Suppl C:S3-14. https://doi.org/10.1016/S0954-6111(03)80020-3
  64. Pelletier-Fleury N, Lanoe JL, Fleury B, Fardeau M. The cost of treating COPD patients with long-term oxygen therapy in a French population. Chest 1996;110:411-6. https://doi.org/10.1378/chest.110.2.411
  65. Jubran A, Gross N, Ramsdell J, Simonian R, Schuttenhelm K, Sax M, et al. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease: a three-center study. Chest 1993;103:678-84. https://doi.org/10.1378/chest.103.3.678
  66. Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, et al. Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. Respir Med 2019;153:68-75. https://doi.org/10.1016/j.rmed.2019.05.017
  67. Dzingina MD, Reilly CC, Bausewein C, Jolley CJ, Moxham J, McCrone P, et al. Variations in the cost of formal and informal health care for patients with advanced chronic disease and refractory breathlessness: a cross-sectional secondary analysis. Palliat Med 2017;31:369-77. https://doi.org/10.1177/0269216317690994
  68. Chu HH, Lee KS, Lee KH, Chung JH, Shin KC, Hwang TY. Association of physical and psychological health status between chronic obstructive pulmonary disease patients and their family caregivers. Health Care Women Int 2019;40:1019-30. https://doi.org/10.1080/07399332.2019.1617292
  69. Ladziak N, Albanese NP. Effect of changing COPD triple-therapy inhaler combinations on COPD symptoms. Am J Manag Care 2019;25:201-4.
  70. Bangdiwala SI, Fonn S, Okoye O, Tollman S. Workforce resources for health in developing countries. Public Health Rev 2010;32:296-318. https://doi.org/10.1007/BF03391604
  71. Bollmeier SG, Seaton TL, Prosser TR, Chou YT, Reckenberg K, Hahn B, et al. Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting. J Am Pharm Assoc (2003) 2019;59:479-88. https://doi.org/10.1016/j.japh.2019.04.017
  72. Bikmoradi A, Jalalinasab A, Salvati M, Ahmadpanah M, Divani F, Roshanaei G. Impact of continuity of care on quality of life in patients with chronic obstructive pulmonary disease: a quasi-experimental study. J Integr Care 2019;27:26-36. https://doi.org/10.1108/JICA-04-2018-0033
  73. Kar S, Zengin N. The relation between self-efficacy in patients with chronic obstructive pulmonary disease and caregiver burden. Scand J Caring Sci 2020;34:754-61. https://doi.org/10.1111/scs.12780
  74. Halpern MT, Zilberberg MD, Schmier JK, Lau EC, Shorr AF. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Eff Resour Alloc 2006;4:17.
  75. Patel JG, Nagar SP, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis 2014;9:289-300. https://doi.org/10.2147/COPD.S57157
  76. Faria BC, Vale JW, Facin AL, De Carvalho MM. Main challenges in the identification and measurement of indirect costs in projects: a multiple case study. Gest Prod 2020;27:e4913.
  77. Cook NS, Kostikas K, Gruenberger JB, Shah B, Pathak P, Kaur VP, et al. Patients' perspectives on COPD: findings from a social media listening study. ERJ Open Res 2019;5:00128-2018. https://doi.org/10.1183/23120541.00128-2018
  78. Iyer AS, Dionne-Odom JN, Ford SM, Crump Tims SL, Sockwell ED, Ivankova NV, et al. A formative evaluation of patient and family caregiver perspectives on early palliative care in chronic obstructive pulmonary disease across disease severity. Ann Am Thorac Soc 2019;16:1024-33. https://doi.org/10.1513/AnnalsATS.201902-112OC
  79. Aumann I, Tedja L, von der Schulenburg JM. Experiences of COPD patients with existing smoking cessation programs and their preferences for improvement: a qualitative analysis. Tob Induc Dis 2016;14:31.
  80. Mills A. Economic aspects of health insurance: the economics of health in developing countries. Oxford: Oxford University Press; 1983.
  81. Miravitlles M, D'Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res 2016;17:112.
  82. Folch-Ayora A, Orts-Cortes MI, Macia-Soler L, Andreu-Guillamon MV, Moncho J. Patient education during hospital admission due to exacerbation of chronic obstructive pulmonary disease. Effects on quality of life: controlled and randomized experimental study. Patient Educ Couns 2019;102:511-9. https://doi.org/10.1016/j.pec.2018.09.013